212 related articles for article (PubMed ID: 20332317)
21. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
[TBL] [Abstract][Full Text] [Related]
22. Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.
Moi LL; Flågeng MH; Gjerde J; Madsen A; Røst TH; Gudbrandsen OA; Lien EA; Mellgren G
BMC Cancer; 2012 Jun; 12():247. PubMed ID: 22703232
[TBL] [Abstract][Full Text] [Related]
23. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of AIB1 expression in human breast cancer.
Iwase H; Omoto Y; Toyama T; Yamashita H; Hara Y; Sugiura H; Zhang Z
Breast Cancer Res Treat; 2003 Aug; 80(3):339-45. PubMed ID: 14503806
[TBL] [Abstract][Full Text] [Related]
25. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
[TBL] [Abstract][Full Text] [Related]
26. Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas.
Carroll RS; Brown M; Zhang J; DiRenzo J; Font De Mora J; Black PM
Clin Cancer Res; 2000 Sep; 6(9):3570-5. PubMed ID: 10999746
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
28. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
[TBL] [Abstract][Full Text] [Related]
29. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
30. Wwox and Ap2gamma expression levels predict tamoxifen response.
Guler G; Iliopoulos D; Guler N; Himmetoglu C; Hayran M; Huebner K
Clin Cancer Res; 2007 Oct; 13(20):6115-21. PubMed ID: 17947476
[TBL] [Abstract][Full Text] [Related]
31. Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer.
Burandt E; Jens G; Holst F; Jänicke F; Müller V; Quaas A; Choschzick M; Wilczak W; Terracciano L; Simon R; Sauter G; Lebeau A
Breast Cancer Res Treat; 2013 Feb; 137(3):745-53. PubMed ID: 23322234
[TBL] [Abstract][Full Text] [Related]
32. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1.
Fleming FJ; Myers E; Kelly G; Crotty TB; McDermott EW; O'Higgins NJ; Hill AD; Young LS
J Clin Pathol; 2004 Oct; 57(10):1069-74. PubMed ID: 15452162
[TBL] [Abstract][Full Text] [Related]
33. Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.
Karmakar S; Foster EA; Blackmore JK; Smith CL
Endocr Relat Cancer; 2011 Feb; 18(1):113-27. PubMed ID: 21059860
[TBL] [Abstract][Full Text] [Related]
34. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.
Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Buggy Y; Young LS
Clin Cancer Res; 2005 Mar; 11(6):2111-22. PubMed ID: 15788656
[TBL] [Abstract][Full Text] [Related]
35. The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease.
Gojis O; Rudraraju B; Alifrangis C; Krell J; Libalova P; Palmieri C
Eur J Surg Oncol; 2010 Mar; 36(3):224-9. PubMed ID: 19716257
[TBL] [Abstract][Full Text] [Related]
36. A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells.
Lauritsen KJ; List HJ; Reiter R; Wellstein A; Riegel AT
Oncogene; 2002 Oct; 21(47):7147-55. PubMed ID: 12370804
[TBL] [Abstract][Full Text] [Related]
37.
Jahangiri R; Mosaffa F; Emami Razavi A; Teimoori-Toolabi L; Jamialahmadi K
J Oncol Pharm Pract; 2022 Mar; 28(2):310-325. PubMed ID: 33509057
[TBL] [Abstract][Full Text] [Related]
38. The p160 ER co-regulators predict outcome in ER negative breast cancer.
Spears M; Oesterreich S; Migliaccio I; Guiterrez C; Hilsenbeck S; Quintayo MA; Pedraza J; Munro AF; Thomas JS; Kerr GR; Jack WJ; Kunkler IH; Cameron DA; Chetty U; Bartlett JM
Breast Cancer Res Treat; 2012 Jan; 131(2):463-72. PubMed ID: 21390497
[TBL] [Abstract][Full Text] [Related]
39. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1.
McBryan J; Theissen SM; Byrne C; Hughes E; Cocchiglia S; Sande S; O'Hara J; Tibbitts P; Hill AD; Young LS
Cancer Res; 2012 Jan; 72(2):548-59. PubMed ID: 22108824
[TBL] [Abstract][Full Text] [Related]
40. Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
Alkner S; Bendahl PO; Ehinger A; Lövgren K; Rydén L; Fernö M
PLoS One; 2016; 11(3):e0150977. PubMed ID: 26959415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
